198 related articles for article (PubMed ID: 36709172)
1. [Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma].
Tang SH; Tian L; Zhao W; Wang J; Ke XY
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):771-777. PubMed ID: 36709172
[No Abstract] [Full Text] [Related]
2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Xu P; Sun X; Song X; Peng Y; He B; Wu Z; Zhu J
Medicine (Baltimore); 2021 Jan; 100(4):e24449. PubMed ID: 33530253
[TBL] [Abstract][Full Text] [Related]
4. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
5. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract][Full Text] [Related]
6. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract][Full Text] [Related]
7. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
[No Abstract] [Full Text] [Related]
8. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
10. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
11. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
[TBL] [Abstract][Full Text] [Related]
13. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
14. Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
Chen H; Qin Y; Liu P; Yang J; Gui L; He X; Zhang C; Zhou S; Zhou L; Yang S; Shi Y
Mol Diagn Ther; 2023 Jan; 27(1):75-86. PubMed ID: 36401148
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
Huang P; Chen S; Yang X; Lei YY; Xu XY; Liu YX; Guo YH; Pan Y; Wang XH; Zhang HL; Fu K; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):589-593. PubMed ID: 32397023
[No Abstract] [Full Text] [Related]
16. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
17. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
19. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
[TBL] [Abstract][Full Text] [Related]
20. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]